Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing innovative drug delivery technologies and products. The company primarily operates in Canada and the U.S., with a portfolio that includes products like Aequus' transdermal delivery systems and a proprietary formulation of tacrolimus for transplant patients.
Aequus generates revenue through the sale of its proprietary pharmaceutical products and through licensing agreements with larger pharmaceutical companies. The company leverages its unique drug delivery technologies to enhance the bioavailability and patient compliance of existing drugs, providing a competitive edge in the specialty pharmaceuticals market.
FDA approval of new drug formulations or delivery systems
Partnership announcements with larger pharmaceutical companies
Changes in market access or reimbursement policies in Canada and the U.S.
Clinical trial results for pipeline products
Regulatory changes affecting drug approval processes
Technological disruption in drug delivery systems
Emergence of generic competitors for existing products
Potential for larger pharmaceutical companies to develop similar technologies
Negative operating cash flow impacting liquidity
Low current ratio indicating potential short-term liquidity issues
moderate - The demand for specialty pharmaceuticals can be somewhat insulated from economic downturns, but overall healthcare spending is influenced by GDP growth.
Interest rates affect Aequus primarily through the cost of capital for R&D funding. Higher rates could increase financing costs and pressure valuations.
minimal - Aequus has a low debt-to-equity ratio, indicating limited reliance on external credit.
growth - Investors looking for high-growth potential in the specialty pharmaceuticals sector.
high - The stock has shown significant volatility, particularly with recent performance trends.
